Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3170416"]Endo rises on analyst upgrade and profit estimates</p><p>Endo Pharma upgraded before FDA ruling on Fortesta; analyst says profits will top views</p><p><br /></p><p>On Monday October 5, 2009, 12:22 pm EDT</p><p> Buzz up! 0 Print.Companies:Endo Pharmaceuticals Holdings Inc.</p><p>NEW YORK (AP) -- Shares of Endo Pharmaceutical Holdings Inc. rose Monday after an analyst upgraded the stock, predicting better-than-expected third-quarter and full-year results for Endo.</p><p><br /></p><p>Oppenheimer analyst John Newman raised his rating to "Outperform" from "Perform" and set a price target of $27 per share, which would be an 18-month high for shares of the Chadds Ford, Pa., company. Newman thinks Endo will surpass Wall Street's profit expectations, and he said its testosterone injection Fortesta will be approved later this month.</p><p><br /></p><p>In midday trading, Endo stock rose $1.59, or 7.2 percent, to $23.70. The shares have traded between $13.87 and $26.14 over the last year.</p><p><br /></p><p>Newman expects Endo to earn a profit of 65 cents per share in the third quarter, which is a penny ahead of Wall Street estimates. He projects a profit of $2.72 per share for the year, which is more than Endo is forecasting. Thomson Reuters says analysts are expecting $2.70 per share.</p><p><br /></p><p>Fortesta is a long-acting injectable testosterone replacement, and is designed for use by men whose bodies do not produce enough of the hormone. Endo bought the U.S. rights to Fortesta from its developer, ProStrakan Group, in August.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3170416"]Endo rises on analyst upgrade and profit estimates Endo Pharma upgraded before FDA ruling on Fortesta; analyst says profits will top views On Monday October 5, 2009, 12:22 pm EDT Buzz up! 0 Print.Companies:Endo Pharmaceuticals Holdings Inc. NEW YORK (AP) -- Shares of Endo Pharmaceutical Holdings Inc. rose Monday after an analyst upgraded the stock, predicting better-than-expected third-quarter and full-year results for Endo. Oppenheimer analyst John Newman raised his rating to "Outperform" from "Perform" and set a price target of $27 per share, which would be an 18-month high for shares of the Chadds Ford, Pa., company. Newman thinks Endo will surpass Wall Street's profit expectations, and he said its testosterone injection Fortesta will be approved later this month. In midday trading, Endo stock rose $1.59, or 7.2 percent, to $23.70. The shares have traded between $13.87 and $26.14 over the last year. Newman expects Endo to earn a profit of 65 cents per share in the third quarter, which is a penny ahead of Wall Street estimates. He projects a profit of $2.72 per share for the year, which is more than Endo is forecasting. Thomson Reuters says analysts are expecting $2.70 per share. Fortesta is a long-acting injectable testosterone replacement, and is designed for use by men whose bodies do not produce enough of the hormone. Endo bought the U.S. rights to Fortesta from its developer, ProStrakan Group, in August.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>